What is SPRAVATO® (esKetamine nasal spray)

SPRAVATO® is the only FDA-approved nasal spray for Treatment-Resistant Depression.

Spravato is a nasal spray that delivers esKetamine into the body through the nose creating relief from symptoms related to treatment-resistant Depression, PTSD, and Suicidal ideation. The FDA approved esketamine (Spravato) for the treatment of Depression in 2019 and for Suicidal ideation in 2020. With FDA approval, comes acceptance from health insurance providers. Making SPRAVATO® an excellence choice for patients that can not afford out of pocket Ketamine infusions.

SPRAVATO® is only administered in the office through a nasal spray under the direct supervision of a healthcare provider. 

Secondary option during nationwide Ketamine shortage.

Hospitals and clinics across the nation are struggling to source enough Ketamine to keep up with the demand. SPRAVATO® (esKetamine) is not experiencing the same shortage allowing our clinic to have secondary option to offer our patients. Allowing us to avoid interruptions or delays in your treatment